RxDoctor Payments Data

Frank Genese, DO

Pulmonary Disease · Rochester, NYNPI 1619310190

Payments from drug & device makers

$1,801in general payments, 2019–2025

Across 59 payments — averaging $30.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$360
  • GSK$303
  • AstraZeneca$227
  • Boehringer Ingelheim$220
  • Electromed, Inc.$214
  • Sanofi$175
  • plus $302 from 6 others

What the payments were for

  • Consulting fees$36020%
  • Food & beverage$1,44180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,801 in reported general payments places this provider in the 55th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$27,759
Medicare patients
136
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate29$361,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter168$113,298
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr95$44,559
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,749
SymbicortBudesonide/Formoterol Fumarate19$5,789
Spiriva HandihalerTiotropium Bromide11$5,656
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,095
Incruse ElliptaUmeclidinium Bromide13$4,323
Albuterol Sulfate HfaAlbuterol Sulfate86$2,735
Azithromycin40$880
Montelukast Sodium74$206
Prednisone25$172
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$89
Pantoprazole Sodium45$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$220$368,69343 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$303$162,179276 claims
AstraZenecaSymbicort$227$5,78919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →